U
AVNR

UBS’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

UBS’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$240K Buy
20,100
+20,000
+20,000% +$137K ﹤0.01% 4999
2014
Q2 		$1K Sell
100
-8,600
-99% -$39.6K ﹤0.01% 10324
2014
Q1 		$32K Sell
8,700
-7,900
-48% -$30.1K ﹤0.01% 7466
2013
Q4 		$56K Buy
16,600
+16,400
+8,200% +$67.7K ﹤0.01% 6817
2013
Q3 		$1K Sell
200
-1,900
-90% -$9K ﹤0.01% 10250
2013
Q2 		$10K Buy
+2,100
New +$7.22K ﹤0.01% 8679

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return

UBS's AVNR Position: Q3 2014 in Review

UBS increased its AVANIR PHARMACEUTICALS, INC CL A (AVNR) stake by 83% in Q3 2014, buying an estimated $543K and bringing the position to 174,874 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #2877.

UBS first reported a position in AVNR in Q2 2013 and has held it in 6 quarters since. 142 funds tracked by Wall St. Rank hold AVNR as of Q3 2014.

  • UBS held 174,874 shares of AVANIR PHARMACEUTICALS, INC CL A worth $2.08M as of Q3 2014.
  • UBS bought 79,520 AVANIR PHARMACEUTICALS, INC CL A shares in Q3 2014, an estimated $543K.
  • AVANIR PHARMACEUTICALS, INC CL A made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2877 holding.
  • UBS first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and has held it in 6 quarters since.
  • 142 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.